Today’s show is about hepatic impairment clinical studies. I cover the rationale behind evaluating hepatic impairment, common study designs, and key factors in the analysis and interpretation of the study results. I also share a huge announcement about Aplos NCA, a cloud-based solution for calculating NCA PK parameters. Use the link below to learn more about Aplos NCA.

Links discussed in the show:

• FDA guidance
• EMA guideline
• Aplos Analytics website
• You can connect with me on LinkedIn and send me a message
• Send me a message
• Sign up for my newsletter

Copyright Teuscher Solutions LLC